Tyramine
As of the edition of 20 October 2026, Tyramine is a small molecule: went quiet in 2020; acts on TAAR1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2020
- Kind
- Small molecule
- Registered trials
- 5, 1 stopped early
- Disease areas
- Nervous system; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
4 companies on route A because of this drug.
Companies on route A for this drug
In the product4 companies are on route A because of Tyramine.
See the 4 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TAAR1 | Trace amine-associated receptor 1 | Q96RJ0 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 3 | 0 | 1 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Teva | Lead sponsor of trials | 2000 to now |
| Merck & Co. | Lead sponsor of trials | 2012 to now |
| Bristol Myers Squibb | Lead sponsor of trials | 2018 to now |
| Boehringer Ingelheim | Lead sponsor of trials | 2019 to now |